Low cost biosensor-based molecular differential diagnosis of α-thalassemia (Southeast Asia deletion)

Wangmaung, Nantawan; Promptmas, Chamras; Chomean, Sirinart; Sanchomphu, Chularat; Ittarat, Wanida

doi:10.1515/cclm-2012-0732

Cited by 7 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nano-based detection of the α-thalassemia 1 mutation (SEA deletion) was demonstrated in, yet, another study whereby quartz crystal microbalance (QCM) was developed for the identification of the abnormal gene, using the silver electrode immobilized with a biotinylated probe on the QCM surface. The diagnostic test, using silver thalassemic QCM, proved to be specific, sensitive, rapid, cheap, and field applicable and valid in performing a one-step diagnosis of α-thalassemia1, without the need for a preliminary screening test [ 92 ].…”

Section: Nanobiosensor For the Diagnosis Of Thalassemiamentioning

confidence: 99%

Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment

Tariq

Qadeer²,

Anjum

et al. 2023

Biosensors

View full text Add to dashboard Cite

Thalassemia is a monogenic autosomal recessive disorder caused by mutations, which lead to abnormal or reduced production of hemoglobin. Ineffective erythropoiesis, hemolysis, hepcidin suppression, and iron overload are common manifestations that vary according to genotypes and dictate, which diagnosis and therapeutic modalities, including transfusion therapy, iron chelation therapy, HbF induction, gene therapy, and editing, are performed. These conventional therapeutic methods have proven to be effective, yet have several disadvantages, specifically iron toxicity, associated with them; therefore, there are demands for advanced therapeutic methods. Nanotechnology-based applications, such as the use of nanoparticles and nanomedicines for theragnostic purposes have emerged that are simple, convenient, and cost-effective methods. The therapeutic potential of various nanoparticles has been explored by developing artificial hemoglobin, nano-based iron chelating agents, and nanocarriers for globin gene editing by CRISPR/Cas9. Au, Ag, carbon, graphene, silicon, porous nanoparticles, dendrimers, hydrogels, quantum dots, etc., have been used in electrochemical biosensors development for diagnosis of thalassemia, quantification of hemoglobin in these patients, and analysis of conventional iron chelating agents. This review summarizes the potential of nanotechnology in the development of various theragnostic approaches to determine thalassemia-causing gene mutations using various nano-based biosensors along with the employment of efficacious nano-based therapeutic procedures, in contrast to conventional therapies.

show abstract

Section: Nanobiosensor For the Diagnosis Of Thalassemiamentioning

confidence: 99%